In the final draft guidance rolled out by the National Institute for Health and Care Excellence- NICE, a single-dose Therapy, eladocagene exuparvovec, has been recommended for patients who are more than 18 months old and happen to be suffering from serious aromatic L-amino acid decarboxylase- Aadc Deficiency. Designed to rectify the underlying genetic defect when […]

The post First Gene Therapy Comes Into Picture For AADC Deficiency first appeared on World Pharma Today.